Why Is Organogenesis Stock Trading Lower Friday?
1. ReNu failed to achieve primary endpoint in the second Phase 3 trial. 2. Baseline pain reduction slightly improved but lacks statistical significance. 3. Company plans to meet with FDA for BLA pathway discussions. 4. ReNu has a favorable safety profile despite trial outcomes. 5. ORGO shares fell 15.49% to $3.95 following the announcement.